CD8A and neoplasm: Interestingly, even without addition of TAA, ARNAX decreased tumor growth, which can be explained either by DCs internalizing tumor debris containing TAAs and cross-priming CD8+ T-cells or TLR3 signaling facilitating chemotaxis of the pre-existing CTLs through cytokine production (37, 94).